ARS Pharmaceuticals (SPRY) Change in Receivables (2024 - 2026)
ARS Pharmaceuticals (SPRY) reported Change in Receivables of $839000.0 for Q1 2026, down 25.62% on a YoY basis from $1.1 million in Q1 2025, and up 107.51% sequentially from -$11.2 million in Q4 2025.
ARS Pharmaceuticals (SPRY) Change in Receivables (2024 - 2026) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 3 years of Change in Receivables data on file, last reported at $839000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Receivables fell 25.62% year-over-year to $839000.0; the trailing twelve-month figure through Mar 2026 stood at $16.9 million (up 81.83% YoY), and the FY2025 full-year result was $17.2 million, up 110.46% from the prior year.
- Change in Receivables climbed to $839000.0 in Q1 2026, from -$11.2 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $14.0 million in Q3 2025 to a low of -$11.2 million in Q4 2025.
- A 3-year average of $3.7 million and a median of $1.1 million in 2025 frame the typical range for Change in Receivables.
- Peak annual rise in Change in Receivables reached 1712.03% in 2025, while the deepest fall reached 251.0% in 2025.
- Tracing SPRY's Change in Receivables over 3 years: stood at $7.4 million in 2024, then tumbled by 251.0% to -$11.2 million in 2025, then surged by 107.51% to $839000.0 in 2026.
- Business Quant data shows SPRY's Change in Receivables at $839000.0 in Q1 2026, -$11.2 million in Q4 2025, and $14.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 75.30 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | 839,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 839,000.00 |
| Mar 31, 2026 | 839,000.00 |
| Dec 31, 2025 | -11.18 Mn |
| Dec 31, 2025 | -11.18 Mn |
| Sep 30, 2025 | 14.01 Mn |
| Sep 30, 2025 | 14.01 Mn |
| Jun 30, 2025 | 13.25 Mn |
| Jun 30, 2025 | 13.25 Mn |
| Mar 31, 2025 | 1.13 Mn |
| Mar 31, 2025 | 1.13 Mn |
| Dec 31, 2024 | 7.40 Mn |
| Dec 31, 2024 | 7.40 Mn |
| Sep 30, 2024 | 773,000.00 |
| Sep 30, 2024 | 773,000.00 |